Skip to main content
S&P 5007,704.81+1.80%DOW53,258.14+2.84%NASDAQ25,884.14+2.02%BTC$80,535.00+3.76%ETH$2,432.59+6.02%GOLD$4,078.30+3.50%OIL$88.78-7.61%
Smart Investors Daily
SID Premium
OC

NASDAQ · OCGN

Ocugen, Inc.

Healthcare · Biotechnology

$0.75

Up+$0.12 (+16.67%)

Updated Nov 4, 2026, 5:58 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
409.14M
P/E ratio
-6.72
Dividend yield
0.00%
52-week range
$0.69 – $2.73
Volume
4.99M
Avg. volume
5.08M

Price performance · OCGN

OCGN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

OCGN closed at $0.75 after 21 trading sessions, down 28.35% for the selected period.

Last close
$0.75
Period change
-28.35%
Period low
$0.70
Period high
$1.04
Daily close
View OHLC price history
OCGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.745$0.7899$0.7317$0.74524.99M
Nov 2, 2026$0.72$0.7476$0.7036$0.72475.71M
Oct 30, 2026$0.746$0.76$0.6909$0.70275.42M
Oct 29, 2026$0.78$0.7964$0.7406$0.74425.53M
Oct 28, 2026$0.7698$0.8037$0.7466$0.77649.23M
Oct 27, 2026$0.7225$0.78$0.7101$0.75748.69M
Oct 26, 2026$0.7402$0.75$0.7016$0.70848.31M
Oct 23, 2026$0.7951$0.7951$0.732$0.73978.59M
Oct 22, 2026$0.80$0.835$0.79$0.796.72M
Oct 21, 2026$0.8256$0.83$0.7906$0.81514.32M
Oct 20, 2026$0.79$0.84$0.786$0.81256.66M
Oct 19, 2026$0.8025$0.8149$0.782$0.78734.47M
Oct 16, 2026$0.84$0.84$0.7803$0.78035.15M
Oct 15, 2026$0.8401$0.85$0.79$0.81375.94M
Oct 14, 2026$0.888$0.9197$0.785$0.84129.53M
Oct 13, 2026$0.9454$0.9454$0.87$0.88546.89M
Oct 12, 2026$0.9573$0.9805$0.924$0.94723.27M
Oct 9, 2026$0.9739$0.9955$0.9001$0.955513.34M
Oct 8, 2026$1.01$1.01$0.9601$0.977412.02M
Oct 7, 2026$1.04$1.05$1.00$1.005.22M
Oct 6, 2026$1.05$1.12$1.04$1.045.29M

Latest OCGN news

The latest Smart Investors Daily articles mentioning OCGN.

Stock researchCompany · Overview

OCGN research

Overview

Company profile and research snapshot.

Company profile

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.00
Implied upside
—
Analysts
—
OCGN recent ratings
DateFirmRatingTarget
Sep 10, 2026HC Wainwright & Co.Buy—
May 27, 2026Canaccord GenuityBuy—
Mar 25, 2026Chardan CapitalBuy—
Mar 25, 2026HC Wainwright & Co.Buy—
Mar 17, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a conference call and live webcast on Wednesday, November 4, 2026, at 8:30 a.m. ET to provide a business update and report third quarter 2026 financial results. All related materials will be made available on the Ocugen investor website prior to the start of the call. Conference Call DetailsDate: Wednesday,

Yahoo · Oct 14, 2026

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapiesExpands access to a potential one-time gene therapy for retinitis pigmentosa in a region with high disease prevalence and substantial unmet needAgreement includes upfront license fee and initial development payments up to $4 million, potential sales milestones up to $255 million, and royalties equaling 22% of net s

Yahoo · Oct 6, 2026

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

European Affiliate, based in Amsterdam, to support upcoming marketing authorization submissions, OCU410 Phase 3 development program, and potential commercialization in Europe MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to address blindness diseases, today announced the appointment of Jolanda Crombach, MSc PharmD, as General Manager of the Company’s E

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By